APOE4 gene linked to early onset Alzheimer’s, target for therapeutic intervention

FHS
May 8, 2024
5:20 am

A study published in Nature Medicine delineates how APOE4 homozygosity distinctly accelerates Alzheimer’s disease pathology and biomarkers from the age of 55, suggesting a unique form of the disease and a potential focus for targeted therapies.

Intellia exits hemophilia B pact with Regeneron; Sangamo targets $24M raise

Plus, news about OKYO Pharma: Intellia departs Regeneron deal: The CRISPR biotech disclosed Friday that it had opted out of a partnership with Regeneron to

March 23, 2024

Millions of people are missing from U.S. disability data

Many disabled people are not included in official U.S. data. This is because there is “No Box to Check” to indicate their particular disability on

September 24, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.

APOE4 gene linked to early onset Alzheimer’s, target for therapeutic intervention

Intellia exits hemophilia B pact with Regeneron; Sangamo targets $24M raise

Millions of people are missing from U.S. disability data

Research highlights health risks posed by 2,6-DHNPs in drinking water

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

Subscribe